Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 370 participants.

Also called NCT03080883

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 370 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03080883
Other papers using this trial's data
  • Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial Journal of thrombosis and haemostasis : JTH, 2024-06 DOI, PubMed 38537780 PubMed links an erratum for this paper. Erratum: PMID 39709266

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03080883. Randomized; double masking; primary purpose prevention. Start 2017-07-14 (actual); primary completion 2022-06-07 (actual). Results posted on 2023-12-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Condition
Cerebral Vein Thrombosis
Condition
Hematopoietic and Lymphoid Cell Neoplasm
Condition
Malignant Solid Neoplasm
Condition
Metastatic Malignant Solid Neoplasm
Condition
Splanchnic Vein Thrombosis
Intervention (Drug)
Apixaban
Lead sponsor
Academic and Community Cancer Research United (class: other)
Collaborator
National Cancer Institute (NCI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03080883
Content hash
66f22df3ebbee116580aab796a2265012d8a22a4f07c2f41700c7baabe2a544d